Significant Announcement from Leap Therapeutics
Leap Therapeutics, Inc. (NASDAQ: LPTX), a pioneering biotechnology firm in the realm of targeted and immuno-oncology treatments, has exciting news to share. They are gearing up to unveil the final clinical outcomes from Part B of the DeFianCe study, a pivotal phase 2 trial. This highly anticipated data presentation will occur during a Mini Oral Session at the upcoming European Society for Medical Oncology (ESMO) Congress held in Berlin.
Details of the Mini Oral Session
This Mini Oral Session is expected to attract considerable interest as it will detail findings from the DeFianCe Trial. Titled "DeFianCe Trial: A randomized phase 2 trial of sirexatamab (DKN-01) plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy as second-line therapy in advanced microsatellite stable (MSS) colorectal cancer (CRC)," the session will be presented by Zev A. Wainberg, M.D., an esteemed figure in the medical community and Co-Director of the GI Oncology Program at UCLA.
About the DeFianCe Study
The DeFianCe study is designed to evaluate the efficacy of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, when used in combination with bevacizumab and conventional chemotherapy. This trial uniquely compares the outcomes of patients receiving this innovative treatment against those treated solely with bevacizumab and chemotherapy. The focus is on patients suffering from advanced microsatellite stable colorectal cancer who have previously undergone one systemic therapy for their condition.
Clinical Implications of the Findings
The results presented will provide critical insights into the effectiveness of novel therapeutic combinations in treating advanced CRC—knowledge that may influence future treatment protocols. Efficacy and safety results can significantly impact clinical practices and offer new hope for patients facing challenging diagnoses. By pushing the boundaries of current treatment methodologies, Leap Therapeutics aims to enhance patient outcomes and pave the way for future oncology treatments.
Expectations Ahead of the Congress
The ESMO Congress is a platform where cutting-edge research is shared amongst leading medical professionals and researchers. The presentation will take place on October 19, 2025, at 4:05 p.m. CEST in Cologne Auditorium – CityCube A.
Leap Therapeutics' Commitment
Leap Therapeutics remains dedicated to advancing its pipeline of targeted therapies which includes both the sirexatamab and FL-501 monoclonal antibodies. These innovative treatments target crucial proteins believed to play significant roles in the growth of various cancers.
Company Overview
With a strong focus on unleashing the potential of immuno-oncology, Leap Therapeutics continues to build upon its foundational research. Investors and partners alike are eager for updates as the company navigates through clinical developments that could redefine the landscape of cancer treatment.
Frequently Asked Questions
What is the DeFianCe Study?
The DeFianCe Study is a Phase 2 clinical trial investigating the efficacy of sirexatamab combined with bevacizumab and chemotherapy in treating advanced colorectal cancer.
Who is presenting the findings?
The session will be presented by Dr. Zev A. Wainberg, a prominent figure in the field of oncology.
When will the findings be presented?
The findings will be presented at the ESMO Congress on October 19, 2025, at 4:05 p.m. CEST.
What is the target patient population for the trial?
The trial specifically targets patients with advanced microsatellite stable colorectal cancer who have had prior systemic therapy.
What are the key focuses of Leap Therapeutics?
Leap Therapeutics focuses on developing targeted and immunotherapy approaches aimed at improving outcomes for cancer patients.
